What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Gene
Hans-Peter Hartung mainly focuses on Multiple sclerosis, Immunology, Internal medicine, Pathology and Surgery.
His research on Multiple sclerosis frequently connects to adjacent areas such as Central nervous system disease.
In his research on the topic of Immunology, Neuroscience, Immunotherapy and Encephalomyelitis is strongly related with Disease.
His Internal medicine research integrates issues from Gastroenterology, Placebo and Expanded Disability Status Scale.
His biological study spans a wide range of topics, including Inflammation, Magnetic resonance imaging and Blood–brain barrier.
He has researched Surgery in several fields, including Fingolimod, Fingolimod Hydrochloride and Polyradiculoneuropathy.
His most cited work include:
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". (4139 citations)
- Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (1970 citations)
- Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. (1666 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Multiple sclerosis, Immunology, Internal medicine, Pathology and Neuroscience.
Hans-Peter Hartung combines subjects such as Clinical trial and Disease with his study of Multiple sclerosis.
His work in Immune system, Antibody, T cell, Pathogenesis and Autoimmune disease is related to Immunology.
His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology, Placebo, Surgery and Oncology.
The various areas that Hans-Peter Hartung examines in his Placebo study include Clinical endpoint and Expanded Disability Status Scale.
His Pathology research incorporates elements of Peripheral nervous system and Magnetic resonance imaging.
He most often published in these fields:
- Multiple sclerosis (41.55%)
- Immunology (29.91%)
- Internal medicine (24.03%)
What were the highlights of his more recent work (between 2016-2021)?
- Multiple sclerosis (41.55%)
- Internal medicine (24.03%)
- Placebo (6.76%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Multiple sclerosis, Internal medicine, Placebo, Clinical trial and Family medicine.
Multiple sclerosis is the subject of his research, which falls under Immunology.
Hans-Peter Hartung mostly deals with Antibody in his studies of Immunology.
His work is dedicated to discovering how Internal medicine, Expanded Disability Status Scale are connected with Phases of clinical research and other disciplines.
His Placebo study incorporates themes from Chronic inflammatory demyelinating polyneuropathy and Hazard ratio.
While the research belongs to areas of Family medicine, Hans-Peter Hartung spends his time largely on the problem of Octapharma, intersecting his research to questions surrounding Double blind.
Between 2016 and 2021, his most popular works were:
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (1618 citations)
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis (720 citations)
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. (670 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Gene
Hans-Peter Hartung mostly deals with Multiple sclerosis, Internal medicine, Placebo, Clinical endpoint and Randomized controlled trial.
His biological study focuses on Natalizumab.
His Internal medicine research includes elements of Gastroenterology, Interferon beta-1a and Expanded Disability Status Scale.
The concepts of his Placebo study are interwoven with issues in Data monitoring committee, BIIB033 and Negative regulator.
His Clinical endpoint research is multidisciplinary, relying on both Siponimod, Multicenter trial and Intention-to-treat analysis.
His study in the field of Autoimmunity is also linked to topics like Multifocal motor neuropathy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
